Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
07 Marzo 2024 - 7:22AM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, announced an expanded commercial partnership
with Transformations Care Network ("TCN"), one of the nation's
largest mental health care providers. Under the new agreement,
Neuronetics will be the exclusive supplier of new transcranial
magnetic stimulation (TMS) equipment to TCN, increasing its
NeuroStar TMS footprint and availability to patients.
"We are delighted to be extending our commercial relationship
with TCN, a long-standing, valued customer with a commitment to
providing the best care for their patients," said Keith J.
Sullivan, President and Chief Executive Officer of Neuronetics.
"With the continued increase in the need for mental health
services, we're glad that NeuroStar TMS is a significant part of
TCN's plan to grow and strengthen mental healthcare in their
communities."
With an extensive network of facilities strategically located
across six states and an ambitious roadmap for further expansion,
TCN's comprehensive five-year exclusive agreement with Neuronetics
stands as a pivotal advancement in broadening patient access to
innovative NeuroStar TMS treatments. This is particularly
significant in the context of addressing major depressive disorder
(MDD), including treatment-resistant depression (TRD), a condition
that presents substantial challenges in mental health care due to
the complexity and difficulty in achieving remission with
conventional treatments.
"Transformations Care Network's alliance with NeuroStar is more
than a milestone; it is a tangible manifestation of our vision to
integrate the most advanced treatments in our suite of services,"
said Brian Wheelan, Chief Executive Officer at Transformations Care
Network. "This collaboration will empower our teams across the
network to deliver exceptional care with even greater efficacy,
reinforcing our pledge to provide access to the best possible
mental health solutions."
NeuroStar TMS therapy offers a beacon of hope for individuals
grappling with MDD, providing a non-invasive, FDA-cleared treatment
that has demonstrated efficacy in cases where traditional
pharmacological interventions have failed. By integrating NeuroStar
TMS into its array of mental health services, TCN not only elevates
the standard of care available to patients but also embodies a
forward-thinking approach to mental health treatment. This
initiative underscores a commitment to embracing advanced
technologies and treatments that can make a meaningful difference
in the lives of those affected by some of the most intractable
forms of depression.
To learn more about NeuroStar® Advanced Therapy, visit
www.neurostar.com. To learn more about Transformations Care
Network, visit www.transformationsnetwork.com.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
In the United States, NeuroStar is FDA-cleared for adults with
major depressive disorder (MDD), as an adjunct for adults with
obsessive-compulsive disorder (OCD), and to decrease anxiety
symptoms in adult patients with MDD that may exhibit comorbid
anxiety symptoms (anxious depression). NeuroStar Advanced Therapy
is the leading transcranial magnetic stimulation (TMS) treatment
for MDD in adults with over 6.1 million treatments delivered.
NeuroStar is backed by the largest clinical data set of any TMS
system for depression, including the world’s largest depression
Outcomes Registry. Neuronetics is committed to
transforming lives by offering an exceptional treatment that
produces extraordinary results. For safety and prescribing
information, www.neurostar.com.
About Transformations Care
NetworkTransformations Care Network (“TCN”) stands as a
vanguard in the provision of comprehensive outpatient mental health
care services across the nation. With a network that spans multiple
states and embraces a myriad of individualized brands, including
Northeast Health Services in Massachusetts, New Directions Mental
Health in Pennsylvania, Harmony in West Virginia, Columbia
Associates in the DMV area, and LightHeart Associates in
Washington, TCN's commitment to community-integrated, accessible
mental health care is unwavering. Our services, tailored for a
diverse clientele ranging from children aged five to adults,
encompass a wide range of outpatient mental health care
solutions.
Central to our ethos is the belief in rapid access to quality
care and the relentless pursuit of innovation in mental health care
strategies. Our facilities, deeply woven into the fabric of their
respective communities, offer both in-person and telehealth
services, ensuring that comprehensive care is within reach for
everyone. As a payor-agnostic entity, we proudly accept a broad
spectrum of insurance providers, including Medicaid, Medicare,
Tricare, and a vast array of commercial insurances. This approach,
coupled with our dedicated central intake teams in each market,
facilitates a seamless connection to the vital care our clients
deserve.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Neuronetics (NASDAQ:STIM)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024